TKPHF Statistics
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of 42.27 billion. The enterprise value is 73.01 billion.
| Market Cap | 42.27B |
| Enterprise Value | 73.01B |
Important Dates
The last earnings date was Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.57B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.16, with an EV/FCF ratio of 15.43.
| EV / Earnings | 36.07 |
| EV / Sales | 2.48 |
| EV / EBITDA | 8.16 |
| EV / EBIT | 17.17 |
| EV / FCF | 15.43 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.
| Current Ratio | 1.28 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 4.07 |
| Debt / FCF | 8.28 |
| Interest Coverage | 5.49 |
Financial Efficiency
Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.
| Return on Equity (ROE) | 4.15% |
| Return on Assets (ROA) | 2.77% |
| Return on Capital (ROIC) | 3.29% |
| Revenue Per Employee | 643,904 |
| Profits Per Employee | 41,075 |
| Employee Count | 49,281 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.17% in the last 52 weeks. The beta is 0.50, so Takeda Pharmaceutical Company's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -12.17% |
| 50-Day Moving Average | 27.39 |
| 200-Day Moving Average | 27.25 |
| Relative Strength Index (RSI) | 32.84 |
| Average Volume (20 Days) | 20,636 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of 31.73 billion and earned 2.02 billion in profits. Earnings per share was 1.27.
| Revenue | 31.73B |
| Gross Profit | 20.93B |
| Operating Income | 4.56B |
| Pretax Income | 1.88B |
| Net Income | 2.02B |
| EBITDA | 9.27B |
| EBIT | 4.56B |
| Earnings Per Share (EPS) | 1.27 |
Balance Sheet
The company has 6.00 billion in cash and 39.15 billion in debt, giving a net cash position of -33.16 billion.
| Cash & Cash Equivalents | 6.00B |
| Total Debt | 39.15B |
| Net Cash | -33.16B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 48.31B |
| Book Value Per Share | 30.47 |
| Working Capital | 4.65B |
Cash Flow
In the last 12 months, operating cash flow was 6.12 billion and capital expenditures -1.39 billion, giving a free cash flow of 4.73 billion.
| Operating Cash Flow | 6.12B |
| Capital Expenditures | -1.39B |
| Free Cash Flow | 4.73B |
| FCF Per Share | n/a |
Margins
Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.
| Gross Margin | 65.95% |
| Operating Margin | 14.38% |
| Pretax Margin | 5.93% |
| Profit Margin | 6.38% |
| EBITDA Margin | 29.22% |
| EBIT Margin | 14.38% |
| FCF Margin | 14.91% |
Dividends & Yields
Takeda Pharmaceutical Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 101.62% |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical Company has an Altman Z-Score of 1.17. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.17 |
| Piotroski F-Score | n/a |